Activation of apoptosis signal-regulating kinase 1 (ASK1) in hepatocytes is a key process in
the progression of nonalcoholic steatohepatitis (NASH) and a promising target for treatment …

Nonalcoholic steatohepatitis (NASH) is a progressive disease that is often accompanied by
metabolic syndrome and poses a high risk of severe liver damage. However, no effective …

Non‐alcoholic fatty liver disease (NAFLD) is strongly associated with obesity and may
progress to non‐alcoholic steatohepatitis (NASH) and liver fibrosis. The deficit of …

Activation of apoptosis signal‐regulating kinase 1 (ASK1) is a key driving force of the
progression of nonalcoholic steatohepatitis (NASH) and represents an attractive therapeutic …

Activation of RIPK1-driven cell death and inflammation play important roles in the
progression of nonalcoholic steatohepatitis (NASH). However, the mechanism underlying …

Liver cell death has an essential role in nonalcoholic steatohepatitis (NASH). The activity of
the energy sensor adenosine monophosphate (AMP)–activated protein kinase (AMPK) is …

Nonalcoholic steatohepatitis (NASH) is an unmet clinical challenge due to the rapid
increase in its occurrence but the lack of approved drugs to treat it. Further unraveling of the …

Nonalcoholic steatohepatitis (NASH) is a progressive liver disease and has become a
leading indication for liver transplantation in the United States. The development of effective …

Inhibition of apoptosis signal–regulating kinase 1, a serine/threonine kinase, leads to
improvement in inflammation and fibrosis in animal models of nonalcoholic steatohepatitis …

Hepatocyte apoptosis plays an essential role in the progression of nonalcoholic
steatohepatitis (NASH). However, the molecular mechanisms underlying hepatocyte …